Biovail acquires North American rights to Kyowa Kirin's Parkinson's agent
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has reached the first licensing deal for its troubled Parkinson's disease drug istradefylline (KW-6002), granting Biovail North American rights to the first-in-class adenosine A2A antagonist.